Drugs Containing Excipient (Inactive Ingredient) MALTOSE

« Back to Dashboard

Branded drugs containing MALTOSE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SHIONOGI INC	METHYLIN	methylphenidate hydrochloride	59630-760	MALTOSE

Generic drugs containing MALTOSE excipient

Company	Ingredient	NDC	Excipient
Novel Laboratories Inc	methylphenidate hydrochloride	40032-570	MALTOSE
Lupin PharmaceuticalsInc	methylphenidate hydrochloride	43386-570	MALTOSE
Kamada Ltd	human hepatitis b virus immune globulin	49591-052	MALTOSE

Maltose Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 17, 2026

Maltose is a niche pharmaceutical excipient used primarily as a bulking agent, stabilizer, carrier, and cryoprotectant in selected oral, injectable, and lyophilized formulations. Its commercial outlook is positive but limited by stronger demand for trehalose, sucrose, mannitol, and lactose in many applications. Maltose has cost and availability advantages, but its reducing-sugar chemistry creates formulation risks that restrict use in protein products and some solid-dose systems.

No major excipient supplier publicly reports maltose revenue as a standalone business line. Financial analysis therefore depends on pharmaceutical-grade carbohydrate sales, supplier disclosures, capacity trends, formulation demand, and pricing rather than a separately audited maltose market figure.

What is maltose and why is it used as a pharmaceutical excipient?

Maltose is a reducing disaccharide composed of two glucose units linked through an alpha-1,4 glycosidic bond. Commercial pharmaceutical material is commonly supplied as maltose or maltose monohydrate, depending on the supplier specification and compendial designation.

Its principal excipient functions are:

Function	Formulation use	Commercial rationale
Bulking agent	Lyophilized injectables and powders	Adds cake structure and solids content
Stabilizer	Proteins, peptides, enzymes, and vaccines	Helps maintain structure during drying and storage
Cryoprotectant	Biologics and cell-related products	Reduces stress from freezing and dehydration
Carrier	Oral powders and specialty dosage forms	Supports uniform distribution of active ingredients
Sweetener or diluent	Oral products	Provides sweetness and bulk, although lactose, sucrose, and polyols are more common

Maltose’s reducing character differentiates it from trehalose. Reducing sugars can participate in Maillard reactions with amino groups in proteins, peptides, and some active pharmaceutical ingredients. That chemistry can create degradation, color formation, potency loss, or impurity concerns under certain conditions.

Maltose therefore has greater formulation value where stability testing confirms compatibility and lower value where the product contains reactive amines or requires extended high-temperature storage.

How large is the pharmaceutical maltose excipient market?

A reliable standalone global market size is not publicly disclosed by the principal suppliers. Public market reports typically combine pharmaceutical maltose with food, nutrition, fermentation, sweetener, and industrial carbohydrate markets. Those totals materially overstate the addressable pharmaceutical-excipient segment.

The pharmaceutical market is best viewed as a specialty subsegment of the broader maltose and functional carbohydrate industry. Its value is determined by:

1. Demand for injectable and lyophilized products.
2. Adoption in biologics and vaccine formulation.
3. Availability of compendial, low-endotoxin, and documented grades.
4. Qualification costs for new suppliers.
5. Price spreads between maltose and competing carbohydrates.
6. Regulatory requirements for change control and batch consistency.

The market has a fragmented revenue structure. Bulk maltose volumes are generally lower value than pharmaceutical-grade material, while validated sterile or low-bioburden grades command higher prices.

What is driving maltose excipient demand?

Growth in biologics and lyophilized medicines

Lyophilization remains the strongest pharmaceutical demand driver. Injectable biologics, peptides, vaccines, and specialty products often require a sugar or polyol to protect the active ingredient during freezing, drying, and reconstitution.

Maltose benefits from this trend where its glass-forming and stabilizing properties meet the product’s stability requirements. The opportunity is strongest in products that do not have a high sensitivity to reducing-sugar chemistry.

Growth in biologics is documented across industry and regulatory sources, although the resulting demand is spread across many excipients rather than concentrated in maltose alone (U.S. Food and Drug Administration [FDA], 2023; European Medicines Agency [EMA], 2019).

Demand for alternative carbohydrate excipients

Drug manufacturers increasingly qualify more than one excipient supplier to reduce supply risk. This creates opportunities for maltose producers with pharmaceutical documentation, validated analytical methods, and reliable regional distribution.

Maltose can compete when it offers:

• Lower cost than trehalose.
• Better supply availability than specialty disaccharides.
• Acceptable cake structure in lyophilized products.
• Established regulatory history.
• Consistent water content and particle-size distribution.

Expansion of injectable and specialty formulations

Maltose demand is more exposed to parenteral and specialty formulation growth than to traditional high-volume tablets. In standard oral solid dosage forms, lactose, microcrystalline cellulose, mannitol, starches, and sucrose are usually better established.

Maltose may gain share in selected oral products requiring sweetness, solubility, or a specific carbohydrate profile, but these applications are unlikely to drive rapid market expansion by themselves.

What limits maltose excipient growth?

Reducing-sugar chemistry

The principal technical limitation is maltose’s reducing behavior. Formulators must evaluate interactions with:

• Primary and secondary amines.
• Protein side chains.
• Peptide degradation pathways.
• Container-closure components.
• Trace metals and oxidative impurities.
• Moisture and elevated storage temperatures.

Trehalose is often preferred for biologics because it is nonreducing. Sucrose also has a large regulatory and commercial base in injectable and lyophilized products. Mannitol provides strong bulking and crystallization properties in many freeze-dried formulations.

Product-specific stability requirements

Maltose cannot be selected solely on the basis of excipient functionality. Developers must assess:

• Glass-transition behavior.
• Collapse temperature.
• Reconstitution time.
• Residual moisture.
• Freeze-concentration effects.
• Long-term degradation.
• Interaction with the active ingredient.
• Container-closure compatibility.

This increases development cost and makes substitution difficult after clinical or commercial qualification.

Limited supplier transparency

Maltose is often included within broader carbohydrate portfolios. Suppliers may disclose manufacturing capabilities, quality systems, or product families without reporting maltose-specific capacity, pricing, or margin data.

That limits visibility into market share, contract volumes, and producer profitability.

Which companies supply pharmaceutical-grade maltose?

The competitive market includes carbohydrate manufacturers, excipient specialists, laboratory suppliers, and regional distributors. Publicly visible suppliers may sell maltose for research, food, biotechnology, or pharmaceutical use, but these categories are not interchangeable.

Potential supply channels include:

Supplier category	Typical role	Key qualification issue
Integrated carbohydrate producers	Manufacture maltose syrup, crystals, or derivatives	Pharmaceutical-grade documentation and process controls
Excipient specialists	Provide compendial material and technical support	Batch consistency and regulatory support
Contract manufacturers	Produce custom grades or packaged material	Scale, validation, and continuity
Distributors	Supply regional inventory	Traceability, storage, and change notification
Laboratory catalog vendors	Small-volume research supply	Not necessarily suitable for commercial drug manufacturing

Roquette, DFE Pharma, Merck, Thermo Fisher Scientific, and other large excipient or laboratory suppliers participate in adjacent carbohydrate and formulation markets. Their public portfolios should not be interpreted as evidence that each company reports material maltose pharmaceutical revenue.

The most important competitive differentiators are documentation and qualification support rather than molecule ownership. Customers generally evaluate compendial compliance, impurity profile, bioburden, endotoxin, residual solvents, particle size, water content, packaging, and supply continuity.

How does maltose compare with trehalose, sucrose, mannitol, and lactose?

Excipient	Primary strength	Principal weakness	Relative position versus maltose
Maltose	Functional sugar, bulking, stabilization, potential cost advantage	Reducing chemistry and interaction risk	Baseline
Trehalose	Strong biologic stabilization and nonreducing chemistry	Higher cost in some supply channels	Usually stronger for sensitive biologics
Sucrose	Broad use, low cost, strong regulatory history	Thermal and chemical stability limitations in some products	More established overall
Mannitol	Excellent bulking, crystallization, and cake formation	Can crystallize and reduce stabilization in some systems	Stronger for many freeze-dried products
Lactose	Broad oral-dose use and established supply	Reducing sugar; incompatibility with amines	Stronger in tablets and capsules
Sorbitol	Solubilization and humectant properties	Hygroscopicity and formulation-specific stability	More useful in liquid and oral systems

Maltose’s commercial opportunity is therefore selective. It is more likely to displace another excipient in a formulation-driven project than to become a general-purpose replacement across pharmaceutical manufacturing.

What is the financial trajectory for pharmaceutical maltose?

The financial trajectory is likely to be gradual rather than explosive.

Near-term outlook

Revenue should track:

• New biologic launches.
• Clinical-stage formulation development.
• Demand for lyophilized injectable products.
• Dual-sourcing programs.
• Regional pharmaceutical manufacturing investment.

Pricing is likely to remain sensitive to glucose and starch feedstock costs, energy, purification, packaging, testing, and freight. Pharmaceutical-grade material has a wider price spread over food-grade material because quality systems and batch release requirements add fixed costs.

Medium-term outlook

Maltose suppliers with compendial grades and formulation support can expand margins through:

• Higher-value crystalline or low-impurity grades.
• Custom particle-size specifications.
• Low-endotoxin and low-bioburden products.
• Technical services for lyophilization.
• Regional inventory and supply assurance.
• Long-term supply contracts.

Commodity maltose producers face greater exposure to price competition and food-market cycles. Their margins are likely to be lower unless they move into validated pharmaceutical grades.

Long-term outlook

Long-term growth depends on whether maltose gains adoption in biologic formulations despite the availability of nonreducing alternatives. The strongest scenario is moderate volume growth with premium pricing for qualified grades. The weaker scenario is volume growth in the overall carbohydrate market without meaningful pharmaceutical share expansion.

Maltose is unlikely to become a major standalone pharmaceutical-excipient revenue category comparable to mannitol, lactose, or sucrose. Its value is more likely to accrue as part of a supplier’s broader specialty excipient portfolio.

What regulatory status applies to maltose as an excipient?

Maltose is not approved as a drug active ingredient merely because it is used in a formulation. Regulatory acceptance depends on the route, dosage form, concentration, product quality, and prior use.

Relevant regulatory considerations include:

• FDA Inactive Ingredient Database entries.
• USP-NF or other applicable compendial standards.
• European Pharmacopoeia requirements where applicable.
• ICH quality and impurity expectations.
• Good manufacturing practice controls.
• Route-specific safety and tolerability.
• Residual endotoxin and microbial limits for injectable use.

FDA’s Inactive Ingredient Database is a reference for prior excipient use, but it does not provide blanket approval for every formulation or route (FDA, n.d.-a). Sponsors must still justify the excipient’s quality, safety, concentration, and manufacturing controls in the applicable regulatory submission.

What patents protect maltose excipient products?

Native maltose is an old carbohydrate and is unlikely to support broad, enforceable composition-of-matter exclusivity in its ordinary form. The commercial IP position is more likely to involve:

• Purification processes.
• Crystal form or hydrate control.
• Particle-size engineering.
• Low-endotoxin processing.
• Specific excipient blends.
• Lyophilization compositions.
• Stabilized biologic formulations.
• Manufacturing equipment and process controls.
• Packaging or moisture-control systems.

A maltose supplier may therefore have process know-how or formulation patents without controlling the underlying molecule.

Patent risk is generally low at the raw-material level and higher at the finished-formulation level. A manufacturer entering the market would need to assess freedom to operate for the specific grade, process, formulation, and jurisdiction.

What patent litigation, Orange Book, and Paragraph IV risks exist?

Maltose itself does not have an Orange Book listing because it is an excipient rather than an approved drug product active ingredient. Orange Book patents and Paragraph IV certifications apply to approved drug products and their listed patents, not to the general sale of maltose as a raw material (FDA, n.d.-b).

Likewise:

• There is no conventional maltose Paragraph IV landscape.
• Generic entry risk concerns the finished drug using maltose, not maltose as an ingredient.
• Formulation patents may restrict use in a specific drug product.
• Method-of-use patents may cover a therapeutic product containing maltose.
• Patent disputes are more likely to involve the drug sponsor’s formulation or manufacturing process than the excipient supplier.

Are there licensing deals for maltose pharmaceutical excipients?

Publicly disclosed licensing deals focused solely on pharmaceutical-grade maltose are uncommon. Commercial arrangements are more likely to consist of:

• Supply agreements.
• Distribution agreements.
• Private-label manufacturing.
• Regional commercialization contracts.
• Custom-grade development.
• Technology-transfer arrangements.
• Excipient qualification partnerships.

The absence of disclosed licensing transactions reflects the commodity-to-specialty nature of the product. Maltose is generally purchased through procurement and qualification channels rather than licensed as a proprietary active technology.

What manufacturing and IP barriers affect market entry?

The principal barriers are operational and regulatory rather than patent-based.

A credible pharmaceutical maltose supplier needs:

1. Controlled raw-material sourcing.
2. Validated purification and drying.
3. Defined water content and solid-state properties.
4. Microbial and endotoxin controls.
5. Batch-to-batch analytical consistency.
6. Change-control procedures.
7. Stability data.
8. Global regulatory documentation.
9. Secure packaging and storage.
10. Customer support for formulation development.

The most difficult qualification barrier is not producing maltose. It is demonstrating that every commercial batch has consistent performance in a customer’s formulation and that the supplier can maintain the process for many years without unplanned changes.

What geographic markets offer the strongest growth?

Asia-Pacific is likely to provide the strongest volume opportunity because of pharmaceutical manufacturing growth, expanding generic production, and increasing biologics capacity. Europe and North America remain important for high-value regulated supply, technical qualification, and specialty injectable applications.

Region	Market opportunity	Main constraint
North America	Biologics, specialty injectables, contract development	High qualification and documentation requirements
Europe	Compendial and regulated excipient demand	Strict quality and supply-chain expectations
China	Manufacturing scale and domestic drug production	Supplier qualification and export compliance
India	Generic drugs, injectables, and contract manufacturing	Price sensitivity and regulatory variation
Japan and South Korea	High-quality biologics and specialty products	Conservative supplier qualification
Latin America	Growing pharmaceutical manufacturing	Import dependence and distribution complexity

Regional supply resilience may support premium pricing for suppliers that hold local inventory or maintain dual production sites.

What generic launch risks are relevant to maltose?

Maltose does not create a generic launch barrier by itself unless the finished product depends on a proprietary formulation, a narrow excipient ratio, or a protected manufacturing process.

Generic and biosimilar developers may face:

• Formulation equivalence challenges.
• Stability differences caused by maltose grade.
• Reconstitution or cake-appearance specifications.
• Biologic aggregation or potency concerns.
• Difficulty matching residual moisture.
• Supplier change-control requirements.
• Patent claims covering the finished formulation.

For conventional small-molecule products, maltose is usually a manageable excipient variable. For biologics and lyophilized injectables, changing the carbohydrate can trigger substantial analytical and regulatory work.

Key Takeaways

• Maltose is a niche pharmaceutical excipient with applications in stabilization, bulking, cryoprotection, and selected oral formulations.
• The market has no dependable standalone public revenue figure because suppliers report maltose within broader carbohydrate or excipient portfolios.
• Pharmaceutical demand should grow gradually with biologics, lyophilization, vaccines, and specialty injectables.
• Trehalose, sucrose, and mannitol limit maltose’s market share, particularly in sensitive biologic formulations.
• Maltose’s reducing chemistry is the main technical constraint.
• Native maltose has limited composition-of-matter patent risk.
• Process, grade, purification, and formulation patents can still create targeted freedom-to-operate issues.
• There is no conventional Orange Book or Paragraph IV landscape for maltose as an excipient.
• Financial upside is strongest for suppliers selling qualified, low-impurity, low-endotoxin, and technically supported grades.
• The likely market outcome is moderate growth with premium pricing in validated pharmaceutical applications rather than rapid mass-market adoption.

FAQs About the Maltose Pharmaceutical Excipient Market

Is maltose safe for injectable pharmaceutical products?

Maltose can be used in injectable formulations when the specific product, concentration, route, quality grade, and stability profile are supported by appropriate regulatory data. Injectable use requires tighter control of endotoxin, bioburden, impurities, particulates, and batch consistency.

Why is trehalose often preferred over maltose in biologics?

Trehalose is nonreducing, while maltose is reducing. Trehalose may therefore create fewer risks of Maillard-type interactions with proteins and peptides, although the final selection depends on the formulation and stability data.

Can maltose replace mannitol in a lyophilized drug?

Not automatically. Maltose and mannitol have different crystallization, glass-transition, cake-structure, moisture, and stabilization behavior. Substitution normally requires formulation redevelopment and stability testing.

Does maltose have pharmaceutical-grade GMP manufacturing?

Some suppliers manufacture maltose under pharmaceutical quality systems or offer documented pharmaceutical grades. Food-grade or research-grade maltose should not be assumed to meet commercial drug-manufacturing requirements.

Are maltose excipients subject to drug patent expiration?

The molecule itself is not generally protected by modern drug patents. Patent exposure usually arises from a finished drug formulation, manufacturing process, delivery system, or method of use that includes maltose.

References

European Medicines Agency. (2019). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu/

U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-reference-listed-drugs

U.S. Food and Drug Administration. (2023). Advancing health through innovation: New drug therapy approvals. https://www.fda.gov/drugs/development-approval-process-drugs/drug-innovation

United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary (USP-NF). U.S. Pharmacopeial Convention.